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Abstract
Background: Metastases of malignant melanoma to the bone marrow are very rare. A few case
reports are published in the literature with a known primary site.
Case presentation: Herein we present a case of metastatic malignant melanoma in bone marrow
with occult primary site in a 22- year-old-male. Diagnosis was confirmed by morphology and
immunohistochemistry. A pertinent review of literature is also presented by using relevant articles
indexed in PubMed (National Library of Medicine) database. The search was based on the following
terms: metastasis or metastases, malignant melanoma and bone marrow.
Conclusion: In this report we discuss a rare case of metastatic malignant melanoma to the bone
marrow with an unknown primary. Clinicians must be aware of the varied clinical manifestations of
disseminated malignant melanoma even if the primary site is not evident.
Background
Malignant melanoma accounts for 1–3% of all malignan-
cies with an increasing incidence being seen worldwide
[1]. Metastatic melanoma usually involves draining
lymph nodes and occasionally adjacent skin first, but
eventually metastasizes to distant visceral sites. The lung is
most commonly involved followed by brain, liver, bone
marrow, and intestine [2]. Metastases of melanoma to
bone marrow are rare with widespread dissemination
occurring in only 5–7% of cases [3]. In about 5–15% of
cases, metastatic melanoma is detected in the absence of
an identifiable primary tumor. In these cases it is generally
believed that the primary tumor has regressed [4-6]. A
search of the literature revealed many isolated case reports
of metastatic melanoma to the bone marrow with a
known primary [7]. However metastases to bone marrow
with an occult primary have been reported rarely [8,9].
Herein we report a case of malignant melanoma metasta-
sized to bone marrow with an occult primary site, along
with a relevant review of literature. The case described is
unique, as it describes an unusual clinical presentation of
metastases, diagnosed only after bone marrow examina-
tion.
Case presentation
A -22- year- old male presented with history of weakness,
weight loss and right axillary swelling since two years and
epistaxis and hemoptysis since one month. The swelling
was progressively increasing for the past six months and
did not respond to a three month course of antitubercu-
lous treatment given on the basis of fine needle aspiration
cytology (FNAC), which revealed granulomatous inflam-
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mation and a positive Mantoux test. On examination
patient was febrile, pale and ill- looking with enlarged
right sided supraclavicular and inguinal lymph nodes. On
palpation these lymph nodes were firm, discrete and
mobile. A 10 × 10 cm soft, hot, tender, red and fluctuant
irregular swelling was seen in the right axillary region. On
incision and drainage it yielded about 200 ml of frank
blood suggesting a hematoma. Cytological examination
of the aspirate was not performed. Beneath the swelling,
there was a single, firm, 1 × 1 cm, discrete lymph node,
histopathology of which showed reactive hyperplasia.
Fine needle aspiration cytology of other lymph nodes also
revealed reactive morphology. Ultrasound examination of
right axilla showed a large nodal mass measuring 7.3 × 12
cm seen in right lateral chest wall anterior to the pectoralis
major. A mantoux tuberculin skin test (purified protein
derivative, 5 tuberculin units) was positive with 21 mm of
induration observed 48 hours after administration.
Hematologic examination revealed severe anemia and
thrombocytopenia. Hemogram findings were as follows:
hemoglobin 5.5 gm/dL, white blood cells 7.8 × 109/L, and
platelets 65 × 109/L. Peripheral blood film revealed a leu-
coerythroblastic blood picture. RBCs showed mild ani-
sopokilocytosis. There were microcytes, tear drop cells
and few nucleated RBCs (2/100WBCs). Mild degree of
hypochromia was present. Platelets were reduced on
blood smear. In the differential leucocyte count, neu-
trophils showed mild shift to the left- 2% myelocytes, 2%
metamyelocytes, 46% polymorphs, 40%lymphocyte, 5%
monocytes, and 5% eosinophils. Therefore, the overall
picture of leukoerythroblastosis was considered. Patient
did not respond to hematinics and his cytopenias wors-
ened over time. Despite 15 (5 packed cells, 4 platelets, 6
fresh frozen plasma) transfusions with in a period of 10
days the patient's condition progressively deteriorated.
Bone marrow aspiration yielded no particles but the trails
were cellular and showed replacement of normal marrow
elements by scattered and a few small cohesive clusters of
large abnormal cells having round to mildly irregular
nuclei with coarse chromatin, one to two prominent
nucleoli and abundant amount of cytoplasm. A few cells
showed cytoplasmic vacuolations. On close inspection
some cells and a few background histiocytes showed
brownish cytoplasmic pigmentation (Figure 1). Occa-
sional interspersed erythroid and myeloid precursors were
present, but no megakaryocytes were seen. Bone marrow
iron was grade 1. A tentative report of bone marrow
metastases was conveyed. Trephine biopsy showed
depression of normal hematopoiesis by a diffuse infiltrate
of pleomorphic, loosely cohesive malignant cells having
hyperchromatic nuclei and distinct nucleoli. Cytoplasmic
pigment was present in some tumor cells (Figure 2) and
histiocytes. Coarsening of reticulin fibers was seen. Immu-
nohistochemical staining on trephine biopsy showed that
the tumor cells were negative for cytokeratin, but positive
for S-100 protein and HMB-45 (Figure 3). Finally a defin-
itive report of bone marrow metastases of malignant
melanoma was given with advice to search for the primary
site. Computed tomography (CT) and chest x-ray were
normal. CT and abdominal ultrasound were also within
normal limits. While investigating patient, no previous
history of a skin lesion or surgery was elicited. There was
no past exposure to UV light or organic dyes. Lastly, no
primary site could be identified and patient was referred
to a tertiary centre for chemotherapy.
Bone marrow trephine biopsy shows spindle shaped malig- nant cells with dark brown granules of melanin pigment lying  in the background of extensive fibrosis, H&E × 600 Figure 2
Bone marrow trephine biopsy shows spindle shaped malig-
nant cells with dark brown granules of melanin pigment lying 
in the background of extensive fibrosis, H&E × 600.
Bone marrow aspirate smear shows melanoma cells with  nuclear pleomorphism and intracytoplasmic pigment, Leish- man × 1000 Figure 1
Bone marrow aspirate smear shows melanoma cells with 
nuclear pleomorphism and intracytoplasmic pigment, Leish-
man × 1000.Diagnostic Pathology 2007, 2:38 http://www.diagnosticpathology.org/content/2/1/38
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Discussion
Epithelial tumors of the thyroid, breast, lung, kidney and
prostate commonly metastasize to the marrow [10]. How-
ever bone marrow infiltration of human melanoma is
found in only 7% of in vivo staging procedures and in up
to 45% of autopsy cases [11]. There are a number of
reports of malignant melanoma showing infiltration of
marrow [see Additional File 1] [3,7-10,12-29]. The male
female ratio in reviewed cases was 1.33:1. Age ranged
from 3 to 75 years (median 60; mean 51.5 years). Anemia
was the most common hematologic manifestation (7 of
21 patients) followed by thrombocytopenia, pancytope-
nia and leukoerythroblastosis. One patient had carcinoc-
ythemia at the time of presentation. Most of the reviewed
cases died due to the disseminated disease despite chem-
otherapy. Savage et al [3] studied 97 patients of malignant
melanoma, of these, 5.4% had marrow involvement.
Bone marrow involvement from retroperitoneal, anal,
tonsillar, nasal, osseous and ocular melanoma has been
described [18,24,25,28,29]. Interestingly, Spiller et al
reported a case of giant congenital nevus with metastatic
malignant melanoma in a child [27]. There was no iden-
tifiable change in the nevus to suggest the primary site for
malignant transformation. The Metastatic involvement of
bone marrow by melanoma with an occult primary has
been reported rarely [8,9]. In one such case, history of
intense childhood exposure to ultraviolet light and an
occupational exposure to organic dyes was present [9].
However we did not find past history of such exposures in
the index patient. At initial presentation our patient had a
two year history of weakness and right axillary swelling.
The hemogram showed bicytopenia and leukoerythrob-
lastosis. Extensive bone marrow involvement normally
presents with pancytopenia but surprisingly our patient
had normal white blood cell count with a left shift.
Extreme leukocytosis in a case of metastatic melanoma
has been reported by de Wolff et al [26]. It was attributed
to either bone marrow invasion by metastases or due to
production of cytokines or other mediators by tumor
cells. In contrast, autoimmune neutropenia and thrombo-
cytopenia have been reported in association with malig-
nant melanoma as a rare paraneoplastic phenomenon
[19,30]. Interestingly Bhagwati et al [9] described micro-
angiopathic hemolytic anemia and disseminated intravas-
cular coagulation related to widely disseminated
melanoma. The patient's lymph nodes were unremarka-
ble on histopathology presumably due to hematogenous
dissemination of the tumor. This in itself lends to a very
poor prognosis [31]. Frank blood was obtained on surgi-
cal drainage of axillary swelling. Presumably, axillary
hematoma might have been the site of lymph nodal
metastases which was not revealed as pathologic examina-
tion was not performed on drained fluid. The simultane-
ous presentation of axillary node metastases and bone
marrow involvement is exceptionally rare [11,19]. The
primary site might have regressed over the period of time
in the index patient. Partial regression is a common fea-
ture in melanoma. Total regression is much less common,
but numerous cases in which the primary tumor regressed
completely after giving rise to nodal and distant metas-
tases have been documented. In about 5–15% of the
patients who present initially with metastases of
melanoma, no primary tumor can be found [4-6].
Although the primary tumor may in some instances be in
an internal organ, it was in most instances located in the
skin and regressed spontaneously [32]. Parenthetically,
the prognosis of patients with metastatic malignant
melanoma and an unknown (presumably regressed) pri-
mary is the same as for the patients with an overt primary
malignancy [6]. Malignant melanoma involves bone mar-
row with disseminated disease and is often amelanotic
[20]. However while reviewing literature, we found only
three cases of amelanotic melanoma [20,21,26]. If mela-
nin is found in the tumor cells or macrophages as brown
pigment, the diagnosis is relatively straightforward similar
to the index case. On the other hand, differential diag-
noses of amelanotic melanoma would be other solid
tumors such as lymphomas, carcinomas and metastatic
small round cell tumors. The primary site of the malig-
nant deposits may be extremely difficult to determine on
a morphological basis alone, but their origin can some-
times be inferred from their morphological appearance,
especially in mucous producing carcinoma, squamous
carcinoma, some adenocarcinomas, and in many cases of
metastatic neuroblastoma. Melanoma should be sus-
pected if the tumor comprises of histologically polygonal
Photomicrograph shows strongly immunoreactive tumor  cells for HMB-45 × 400 Figure 3
Photomicrograph shows strongly immunoreactive tumor 
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or spindle cells with prominent nucleoli. Immunohisto-
chemical study is useful in supporting a diagnosis of
malignant melanoma. Typically melanoma is reactive for
vimentin, S-100 protein, HMB-45, melan -A, tyrosinase,
and microphthalmia transcription factor [33]. HMB-45 is
a much more specific marker than S-100 protein [34]. Our
case is in fact entirely typical of malignant melanoma
based on morphology and immunohistochemistry.
Conclusion
Despite the rarity of bone marrow involvement, clinicians
must be aware of the varied clinical manifestations of dis-
seminated malignant melanoma even if the primary site is
not evident.
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